Epidermal growth factor receptors: A functional perspective

Current Radiopharmaceuticals

Volumn 5, Issue 1, 2012, Pages 29-33

  Mitrasinovic, Petar M ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

Cancer; EGFR; Imaging; Peptide radiopharmaceutical; Targeting; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; HEXAPEPTIDE; INDIUM 111; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH806; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRACER; TRANSFERRIN IN 111; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CELL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; GENE OVEREXPRESSION; GENE TARGETING; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOSOMAL DELIVERY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; EARLY DETECTION OF CANCER; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 83455236605     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011205010029     Document Type: Article

References (55)

1. Mach, J.P. In: Oxford Textbook of Oncology, Peckham, M.; Pinedo, H.M.; Veronesi, U., Eds.; Oxford University Press: Oxford, 1995; Vol. 1, pp 81-103.
2. Prenzel, N.; Fischer, O.M.; Streit, S.; Hart, S.; Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer, 2001, 8, 11-31.
3. Nicholson, R.I.; Gee, J.M.; Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer, 2001, 37(Suppl. 4), S9-S15.
4. Libermann, T.A.; Nusbaum, H.R.; Razon, N.; Kris, R.; Lax, I.; Soreq, H.; Whittle, N.; Waterfield, M.D.; Ullrich, A.; Schlessinger, J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature, 1985, 313, 144-147.
5. Wong, A.J.; Bigner, S.H.; Bigner, D.D.; Kinzler, K.W.; Hamilton, S.R.; Vogelstein, B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA, 1987, 84, 6899-6903.
6. Ekstrand, A.J.; James, C.D.; Cavenee, W.K.; Seliger, B.; Pettersson, R.F.; Collins, V.P. Genes for epidermal growth factor receptor, transforming growth factor a, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res., 1991, 51, 2164-2172.
7. Collins, V.P. Amplified genes in human gliomas. Semin. Cancer Biol., 1993, 4, 27-32.
8. Malden, L.T.; Novak, U.; Kaye, A.H.; Burgess, A.W. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res., 1988, 48, 2711-2714.
9. Sugawa, N.; Ekstrand, A.J.; James, C.D.; Collins, V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA, 1990, 87, 8602-8606.
10. Yamazaki, H.; Fukui, Y.; Ueyama, Y.; Tamaoki, N.; Kawamoto, T.; Taniguchi, S.; Shibuya, M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol. Cell. Biol., 1988, 8, 1816-1820.
11. Humphrey, P.A.; Wong, A.J.; Vogelstein, B.; Zalutsky, M.R.; Fuller, G.N.; Archer, G.E.; Friedman, H.S.; Kwatra, M.M.; Bigner, S.H.; Bigner, D.D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor recep tors in human glioblastoma. Proc. Natl. Acad. Sci. USA, 1990, 87, 4207-4211.
12. Jungbluth, A.A.; Stockert, E.; Su Huang, H.J.; Collins, V.P.; Coplan, K.; Iversen, K.; Kolb, D.; Johns, T.J.; Scott, A.M.; Gullick, W.J.; Ritter, G.; Cohen, L.; Scanlan, M.J.; Cavenee, W.K.; Old, L.J. A monoclonal antibody recognizing human cancers with amplification/ overexpression of the human epidermal growth factor receptor. PNAS, 2003, 100, 639-644.
13. Aboud-Pirak, E.; Hurwitz, E.; Pirak, M.E.; Bellot, F.; Schlessinger, J.; Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 1988, 80, 1605-1611.
14. Christen, R.D.; Hom, D.K.; Portor, D.C.; Andrews, P.A.; MacLeod, C.L., Hafstrom, L. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 1990, 86, 1632-1640.
15. Christen, R.D.; Isonishi, S.; Jones, J.A.; Jekunen, A.P.; Hom, D.K.; Kroning, R. Signaling and drug sensitivity. Cancer Metastasis Rev., 1994, 13, 175-189.
16. Kroning, R.; Jones, J.A.; Hom, D.K.; Chuang, C.C.; Sanga, R.; Los, G. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br. J. Cancer, 1995, 72, 615-619.
17. Basu, A.; Evans, R.W. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cisdiamminedichloroplatinum(II). Int. J. Cancer, 1994, 58, 587-591.
18. Bonner, J.A.; Maihle, N.J.; Folven, B.R.; Christianson, T.J.; Spain, K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 243-247.
19. Frankel, A. Mills, G.B. Peptide and lipid growth factors decrease cisplatininduced cisplatininduced cell death in human ovarian cancer cells. Clin. Cancer. Res., 1996, 2, 1307-1313.
20. Kwok, T.T. Epidermal growth factor induced chemosensitization and downregulation of a mutant p53. Proc. Am. Assoc. Cancer Res., 1995, 36, 429-429.
21. Harris, L.; Tang, C.; Yang, D.; Lupu, R. Induction of chemotherapy sensitivity in MCF-7 breast cancer cells by heregulin. Proc. Am. Assoc. Cancer Res., 1995, 36, 426-426.
22. Waldman, T.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 1996, 381, 713-716.
23. Smith, M.L.; Fornace, A.J.Jr. The two faces of tumor suppressor p53. Am. J. Pathol. 1996, 148, 1019-1022.
24. Lowe, S.W. Cancer therapy and p53. Curr. Opin. Oncol., 1995, 7, 547-553.
25. Mendelsohn, J.; Fan, Z. Epidermal growth factor receptor family and chemosensitization. Journal of the National Cancer Institute, 1997, 89, 341-343.
26. Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19, 6550-6565.
27. Kawamoto, T.; Sato, J.D.; Le, A.; Polikoff, J.; Sato, G.H.; Mendelsohn, J. Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal grwoth factor by an antireceptor monoclonal antibody. Proc. Natl. Acad. Sci. USA, 1983, 80, 1337-1341.
28. Waterfield, M.D.; Mayes, E.L.; Stroobant, P.; Bennet, P.L.; Young, S.; Goodfellow, P.N.; Banting, G.S.; Ozanne, B. A monoclonal antibody to the human epidermal growth factor receptor. J. Cell. Biochem., 1982, 20, 149-161.
29. Hills, D.; Rowlinson-Busza, G.; Gullick, W.J. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int. J. Cancer, 1995, 63, 537-543.
30. Wikstrand, C.J.; Hale, L.P.; Batra, S.K.; Hill, M.L.; Humphrey, P.A.; Kurpad, S.N.; McLendon, R.E.; Moscatello, D.; Pegram, C.N.; Reist, C.J. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 1995, 55, 3140-3148.
31. Okamoto, S.; Yoshikawa, K.; Obata, Y.; Shibuya, M.; Aoki, S.; Yoshida, J.; Takahashi, T. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br. J. Cancer, 1996, 73, 1366-1372.
32. 111In]-chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethyleneglycol linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjugate Chem., 1999, 10, 502-511.
33. Kurihara, A.; Pardridge, W.M. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res., 1999, 59, 6159-6163.
34. Beuttler, J.; Rothdiener, M.; Muller, D.; Fredrik, Y.; Frejd, Kontermann, R.E. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjugate Chem., 2009, 20, 1201-1208.
35. Song, S.; Liu, D.; Peng, J.; Deng, H.; Guo, Y.; Xu, L.X.; Miller, A.D.; Xu, Y. Novel peptide ligand directs liposomes toward EGFR high-expressing cancer cells in vitro and in vivo. The FASEB Journal, 2009, 23, 1396-1404.
36. Arteaga, C.L.; Baselga, J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clinical Cancer Research, 2003, 9, 1579-1589.
37. Rusch, V.; Klimstra, D.; Linkov, I.; Dmitrovsky, E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res., 1995, 55, 1365-1372.
38. Kurie, J.M.; Shin, H.J.; Lee, J.S.; Morice, R.C.; Ro, J.Y.; Lippman, S.M.; Hittelman, W.N.; Yu, R.; Lee, J.J.; Hong, W.K. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin. Cancer Res., 1996, 2: 1787-1793.
39. van de Vijver, M.J.; Peterse, J.L.; Mooi, W.J.; Wisman, P.; Lomans, J.; Dalesio, O.; Nusse, R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 1988, 319, 1239-1245.
40. Ke, S.; Wen, X.; Gurfinkel, M.; Charnsangavej, C.; Wallace, S.; Sevick-Muraca, E.M.; Li, C. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res., 2003, 63, 7870-7875.
41. Parulekar, W.R.; Eisenhauer, E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. JNCI J. Natl. Cancer Inst., 2004, 96, 990-997.
42. Scott, A.M.; Lee, F.-T.; Tebbutt, N.; Herbertson, R.; Gill, S.S.; Liu, Z.; Skrinos, E.; Murone, C.; Saunder, T.H.; Chappell, B.; Papenfuss, A.T.; Poon, A.M.T.; Hopkins, W.; Smyth, F.E.; MacGregor, D.; Cher, L.M.; Jungbluth, A.A.; Ritter, G.; Brechbiel, M.W.; Murphy, R.; Burgess, A.W.; Hoffman, E.W.; Johns, T.G.; Old, L.J. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. PNAS, 2007, 104, 4071-4076.
43. Lee, F.T.; O'Keefe, G.J.; Gan, H.K.; Mountain, A.J.; Jones, G.R.; Saunder, T.H.; Sagona, J.; Rigopoulos, A.; Smyth, F.E.; Johns, T.G.; Govindan, S.V.; Goldenberg, D.M.; Old, L.J.; Scott, A.M. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J. Nucl. Med., 2010, 51, 967-972.
44. Morris, M.J.; Pandit-Taskar, N.; Divgi, C.R. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res., 2007, 13, 2707-2713.
45. Johns, T.G.; Adams, T.E.; Cochran, J.R.; Hall, N.E.; Hoyne, P.A.; Olsen, M.J.; Kim, Y.-S.; Rothacker, J.; Nice, E.C.; Walker, F.; Ritter, G.; Jungbluth, A.A.; Old, L.J.; Ward, C.W.; Burgess, A.W.; Wittrup, K.D.; Scott, A.M. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. Journal of Biological Chemistry, 2004, 279, 30375-30384.
46. Jaffer, F.A.; Weissleder, R. Molecular imaging in the clinical arena. The Journal of the American Medical Association, 2005, 293, 855-862.
47. Perera, R.M.; Narita, Y.; Furnari, F.B. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res., 2005, 11, 6390-6399.
48. Li, X.; Lu, Y.; Liang, K.; Pan, T.; Mendelsohn, J.; Fan, Z. Requirement of hypoxia-inducible factor-1A downregulation in mediating the antitumor activity of the anti-epidermal growth factor re ceptor monoclonal antibody cetuximab. Mol. Cancer. Ther., 2008, 7, 1207-1217.
49. Aerts, H.J.W.L.; Dubois, L.; Perk, L.; Vermaelen, P.; van Dongen, G.A.M.S.; Wouters, B.G.; Lambin, P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med., 2009, 50, 123-131.
50. del Carmen, M.G.; Rizvi, I.; Chang, Y.; Moor, A.C.E.; Oliva, E.; Sherwood, M.; Pogue, P.; Hasan, T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. JNCI J. Natl. Cancer Inst., 2005, 97, 1516-1524.
51. Tolmachev, V.; Friedman, M.; Sandstrom, M.; Eriksson, T.L.J.; Rosik, D.; Hodik, M.; Stahl, S.; Frejd, F.Y.; Orlova, A. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J. Nucl. Med., 2009, 50, 274-283.
52. Divgi, C.R. Molecular imaging of pulmonary cancer and inflammation. The Proceedings of the American Thoracic Society, 2009, 6, 464-468.
53. Fernandes, C.; Oliveira, C.; Gano, L.; Santos, I.C.; Santos, I. In: Inorganic and Radiopharmaceutical Chemistry (ITN Annual Report); Santos, I.R., Ed.; Instituto Technológico e Nuclear: Sacavém, 2005; pp. 52-52.
54. Diagaradjane, P.; Orenstein-Cardona, J.M.; Colon-Casasnovas, N.E.; Deorukhkar, A.; Shentu, S.; Kuno, N.; Schwartz, D.L.; Gelovani, J.G.; Krishnan, S. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin. Cancer Res., 2008, 14, 731-741.
55. Melancon, M.P.; Lu, W.; Yang, Z.; Zhang, R.; Cheng, Z.; Elliot, A.M.; Stafford, J.M.; Olson, T.; Zhang, J.Z.; Li, C. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol. Cancer Ther., 2008, 7, 1730-1739.